0001209191-23-059346.txt : 20231220 0001209191-23-059346.hdr.sgml : 20231220 20231220163529 ACCESSION NUMBER: 0001209191-23-059346 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231218 FILED AS OF DATE: 20231220 DATE AS OF CHANGE: 20231220 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GUGGENHIME ANDREW CENTRAL INDEX KEY: 0001230724 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39323 FILM NUMBER: 231501732 MAIL ADDRESS: STREET 1: C/O VAXCYTE, INC. STREET 2: 825 INDUSTRIAL ROAD, STE. 300 CITY: SAN CARLOS STATE: CA ZIP: 94070 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Vaxcyte, Inc. CENTRAL INDEX KEY: 0001649094 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 464233385 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 825 INDUSTRIAL ROAD, STE. 300 CITY: SAN CARLOS STATE: CA ZIP: 94070 BUSINESS PHONE: 650-837-0111 MAIL ADDRESS: STREET 1: 825 INDUSTRIAL ROAD, STE. 300 CITY: SAN CARLOS STATE: CA ZIP: 94070 FORMER COMPANY: FORMER CONFORMED NAME: SutroVax, Inc. DATE OF NAME CHANGE: 20150724 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-12-18 0 0001649094 Vaxcyte, Inc. PCVX 0001230724 GUGGENHIME ANDREW C/O VAXCYTE, INC. 825 INDUSTRIAL ROAD, STE. 300 SAN CARLOS CA 94070 0 1 0 0 President and CFO 1 Common Stock 2023-12-18 4 M 0 8000 5.35 A 87474 D Common Stock 2023-12-18 4 S 0 7883 60.168 D 79591 D Common Stock 2023-12-18 4 S 0 117 60.79 D 79474 D Stock Option (right to buy) 5.35 2023-12-18 4 M 0 8000 0.00 D 2030-05-11 Common Stock 8000 392827 D The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted June 30, 2023. The price reported is a weighted-average price. The shares were sold at prices ranging from $59.79 to $60.77. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. 1/4 of the shares subject to the option vested on May 1, 2021, and 1/48 of the shares vest monthly thereafter. Andrew Guggenhime, by /s/ Ron Metzger, Attorney-in-Fact 2023-12-20